Cart
sales@molnova.com
Bexotegrast
CAS No. 2376257-44-0
Bexotegrast( —— )
Catalog No. M35169 CAS No. 2376257-44-0
Bexotegrast (PLN-74809) is an orally active and potent inhibitor of αvβ6 and αvβ1 integrins with antifibrotic effects, inhibiting αvβ6 and αvβ1-induced activation of TGF-β.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 161 | In Stock |
|
| 5MG | 148 | In Stock |
|
| 10MG | 235 | In Stock |
|
| 25MG | 377 | In Stock |
|
| 50MG | 548 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBexotegrast
-
NoteResearch use only, not for human use.
-
Brief DescriptionBexotegrast (PLN-74809) is an orally active and potent inhibitor of αvβ6 and αvβ1 integrins with antifibrotic effects, inhibiting αvβ6 and αvβ1-induced activation of TGF-β.
-
DescriptionBexotegrast (PLN-74809) is an orally active, potent dual αvβ6/αvβ1 integrin inhibitor with Kd of 5.7 nM and 3.4 nM, respectively. Bexotegrast inhibits αvβ6- and αvβ1-induced TGF-β activation with IC50 values of 29.8 nM and 19.2 nM, respectively. Bexotegrast has antifibrogenic effects and block multiple avenues of TGF-β activation in the fibrotic lung.
-
In Vitro——
-
In VivoAnimal Model:C57BL/6 mice Dosage:100, 250, and 500 mg/kg Administration:Orally; twice daily; from Day 7 to Day 21 Result:Showed a dose-dependent, significant reduction in interstitial fibrillar collagen deposition in Bleomycin (3 units/kg)-challenged mice. Dose-dependently blocked Smad3 phosphorylation.
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
RecptorIntegrin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2376257-44-0
-
Formula Weight492.61
-
Molecular FormulaC27H36N6O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (507.50 mM; Ultrasonic )
-
SMILESN([C@@H](CCN(CCCCC=1NC=2C(=CC1)CCCN2)CCOC)C(O)=O)C=3C4=C(N=CN3)C=CC=C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Anindya Roy, et al. De novo design of highly selective miniprotein inhibitors of integrins αvβ6 and αvβ8. Nat Commun. 2023 Sep 13;14(1):5660.?
molnova catalog
related products
-
Tadocizumab
Tadocizumab (C4G1) is a humanized monoclonal antibody targeting integrin αIIbβ3 with antiplatelet and antithrombotic activity that blocks the platelet αIIbβ3 integrin interac- with brinogen and bronectin, and can be used in the study of cardiovascular disease.
-
Abrilumab
Abrilumab (MEDI-7183) is a fully human monoclonal antibody against α4β7 that inhibits the α4β7 integrin and can be used to study inflammatory bowel disease and ulcerative colitis.
-
Cyclo(-RGDfK)
A RGD pipetide, potent and selective αvβ3 integrin inhibitor with Kd of 41.7 nM.
